Meeting
2018 ASCO Annual Meeting
Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naïve prostate cancer (mHNPC).
Authors
Chethan Ramamurthy
Fox Chase Cancer Center, Philadelphia, PA
Chethan Ramamurthy , Andres F Correa , Elizabeth A. Handorf , J Robert Beck , Daniel M. Geynisman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Health Services Research, Clinical Informatics, and Quality of Care
Track
Quality Care/Health Services Research
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 36, 2018 (suppl; abstr 6514)
DOI
10.1200/JCO.2018.36.15_suppl.6514
Abstract #
6514
Poster Bd #
340
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
SPOP mutations in prostate cancer: Clinical and genomic features.
First Author: Mari Nakazawa
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay
Poster
2024 ASCO Genitourinary Cancers Symposium
Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS.
First Author: Nataniel Hernan Lester-Coll
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan